Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

- Annualized serious bacterial infection rates were ≤ 0.06 per subject per year.
- Annualized rates of any infection were low among subjects across a wide age range.
- Lower rates of bronchopulmonary infections were observed with higher doses of SCIG.
- No treatment-related discontinuations occurred, supporting long-term tolerability.
- Weekly infusions were well tolerated throughout a treatment period of up to 3 years.

Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4-69 years) were treated for 148 weeks in the EU (N = 40; 5405 infusions) and 87 weeks in the US (N = 21; 1735 infusions). Weekly doses were 116.0 mg/kg (EU) and 193.2 mg/kg (US); IgG levels were 7.97 g/L (EU) and 11.98 g/L (US). Annualized rates of serious bacterial infections were 0.05 infections/subject/year (EU) and 0.06 infections/subject/year (US). Rates of any infection were 3.33 infections/subject/year (EU) and 2.38 infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3 years.